News Conference News ACC 2026 Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering Michael O'Riordan April 01, 2026
News Conference News ACC 2026 SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients Michael O'Riordan March 30, 2026
News Conference News ACC 2026 PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV Michael O'Riordan March 29, 2026
News Conference News ACC 2026 Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE Yael L. Maxwell March 28, 2026
News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News ESC 2025 WHF Stresses the Importance of Polypills in Global Fight Against CVD Yael L. Maxwell September 09, 2025
News Conference News ESC 2025 NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure Michael O'Riordan September 04, 2025
News Conference News ESC 2025 HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI Todd Neale September 03, 2025
News Conference News SCCT 2025 AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD Yael L. Maxwell July 22, 2025
News Conference News SCCT 2025 AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry Yael L. Maxwell July 21, 2025
News Conference News EuroPCR 2025 ‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI Michael O'Riordan May 29, 2025
News Conference News EuroPCR 2025 Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI L.A. McKeown May 22, 2025
News Conference News European Congress on Obesity 2025 SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly Michael O'Riordan May 14, 2025
News Conference News ACC 2025 RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI Michael O'Riordan April 02, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III Caitlin E. Cox November 21, 2024